Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia
- PMID: 33411170
- DOI: 10.1007/s10096-020-04118-w
Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia
Abstract
In the non-AIDS group, several underlying conditions and immune defects could lead to different PCP presentations. This study compared PCP presentation and outcome according to the underlying disease. A secondary analysis of a previously published prospective observational study including 544 PCP patients was done. Only non-AIDS patients were included. Underlying disease was defined as chronic lymphocytic leukemia (CLL), organ transplantation, solid cancer, allogeneic hematopoietic stem cell transplant (AHSCT), other hematological diseases, and immunosuppressive treatment. Clinical characteristics and outcomes were compared between groups. Multiple correspondent analyses compared clinical characteristics at diagnosis. Day 30 mortality was analyzed. Three hundred and twenty-one patients were included in the study. The underlying diseases were hematological malignancy (n = 75), AHSCT (n = 14), CLL (n = 19), solid organ transplant (n = 94), solid tumor (n = 39), and immunosuppressive treatment (n = 57). Compared with other underlying diseases, PCP related to CLL was closer to PCP related to AIDS presentation (long duration of symptoms before diagnosis, high level of dyspnea, and low oxygen saturation at diagnosis). Day 30 mortality was associated with underlying disease, oxygen flow, and shock at ICU admission. PCP presentations may vary according to the underlying reason for immunosuppression. Response to treatment and adjuvant steroid therapy should be analyzed regarding this result.
Keywords: ICU; Immunosuppression; Outcome; Pneumocystis.
References
-
- Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Menotti J et al (2007) Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 132:1305–1310 - DOI
-
- Gonzalez Santiago TM, Wetter DA, Kalaaji AN, Limper AH, Lehman JS (2016) Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol 55:823–830 - DOI
-
- Matsumoto T, Fujita M, Hirano R, Sasaki T, Watanabe K (2019) Risk factors for pneumocystis pneumonia onset in HIV-negative patients treated with high-dose systemic corticosteroids. Infect Dis (Lond) 51:305–307 - DOI
-
- Park SY, Jung JH, Kwon H, Shin S, Kim YH, Chong Y et al (2020) Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study. Transpl Infect Dis 22(2):e13245 - DOI
-
- Watanabe H, Kitahara Y, Murakami Y, Nihashi F, Matsushima S, Eifuku T et al (2020) Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy. Intern Med 59:987–990 - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

